Meanwhile, the BSE Sensex was down 143.33 points, or 0.75%, to 18,999.67.
On BSE, 95,953 shares were traded in the counter as against an average daily volume of 3.37 lakh shares in the past one quarter.
The stock hit a high of Rs 172.70 and a low of Rs 167.10 so far during the day. The stock had hit a 52-week high of Rs 204.90 on 7 January 2013. The stock had hit a 52-week low of Rs 99.65 on 10 August 2012.
The stock underperformed the market over the past one month till 11 June 2013, declining 11.73% compared with the Sensex's 4.87% slide. The scrip, however, outperformed the market in past one quarter, rising 2.93% as against Sensex's 2.56% slide.
The mid-cap pharma company has an equity capital of Rs 29.12 crore. Face value per share is Rs 1.
Shares of Aurobindo Pharma have fallen 8.77% in three trading days from a recent high of Rs 184.15 on 10 June 2013. In a disclosure issued during market hours on 10 June 2013, Aurobindo Pharma said that Life Insurance Corporation of India (LIC) sold 58.56 lakh shares or 2.01% stake in Aurobindo Pharma through open market between 4 August 2011 and 6 June 2013. Post the sale, LIC's stake in Aurobindo Pharma declined to 3.03% from 5.04%.
On a consolidated basis, Aurobindo Pharma reported 0.6% rise in net profit to Rs 108.61 crore on 32.6% rise in net sales to Rs 1552.68 crore in Q4 March 2013 over Q4 March 2012.
Aurobindo Pharma, headquartered at Hyderabad in Andhra Pradesh, manufactures generic pharmaceuticals and active pharmaceutical ingredients (APIs). The company's product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics. The company is marketing these products globally, in over 125 countries.
Powered by Capital Market - Live News
